All
Blincyto Granted FDA Approval for Leukemia Subset
July 12th 2017Blincyto (blinatumomab) was granted full approval by the Food and Drug Administration (FDA) to treat both children and adults with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (ALL), regardless of Philadelphia chromosome (Ph) status, according to the developer of the anti-CD19 immunotherapy, Amgen.
Abemaciclib Gets a Priority Review to Treat Breast Cancer Subset
July 12th 2017Abemaciclib was granted a priority review to a new drug application (NDA) to treat patients with advanced hormone receptor (HR)­­–positive, HER2-negative breast cancer, according to Eli Lilly and Company, the manufacturer of the CDK4/6 inhibitor.
Maintenance Rubraca Has Potential in Ovarian Cancer
July 9th 2017For women with platinum-sensitive, high-grade ovarian, fallopian tube or primary peritoneal cancer, an improved progression-free survival (PFS) was seen for those who took Rubraca (rucaparib) as a maintenance therapy, compared to placebo, according to the phase 3 ARIEL3 trial.